Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2022

View Archived Issues

Genetic findings pave way to treatment of lymph disorder

FSH blockade improves cognition in preclinical models of AD

Chinese investigators patent PAK4 inhibitors

Shenzhen Chipscreen Biosciences discloses new PTPN11 inhibitors

Chengdu Easton Pharmaceutical synthesizes new mu-opioid receptor agonists

Medshine Discovery identifies new BRD4 inhibitors

Novartis discloses EZH2 and EED inhibitors

PEAK3 promotes cell proliferation and migration in vitro

Novel UV-mediated antigen-presenting nanoparticles for mRNA delivery to virus-specific T cells

Regulation of BIN1 ameliorates dynamin-related myopathy

Modulation of RICTOR/mTORC2 axis is an approach for sensorineural hearing loss

VYN-201 reduces key inflammatory biomarkers involved in vitiligo pathogenesis in preclinical model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.